Utility of levetiracetam in patients with subarachnoid hemorrhage
Utility of levetiracetam in patients with subarachnoid hemorrhage
复制标题
DOI：
10.1016/j.seizure.2009.09.003
复制
发表时间：
2009-12-01
影响因子：
3
通讯作者：
Husain, Aatif M.
中科院分区：
文献类型：
--
作者：
Shah, Dharmen;Husain, Aatif M.
目的：为了确定左乙拉西坦（LEV）的效用和耐受性相比，苯妥英钠（PHT）在预防临床癫痫发作的患者与蛛网膜下腔出血（SAH）。方法：效用和耐受性PHT和LEV在SAH患者的发生突破性临床癫痫发作或不良事件，需要改变药物。结果：所有176例患者最初均接受PHT治疗。未发生突破性临床癫痫发作。在70例（39.8%）患者中，由于不良事件（包括转氨酶升高、血小板减少、不明原因发热、皮疹、胃肠道紊乱和精神状态恶化），PHT被LEV替代。改用LEV治疗后，除4例患者胃肠道功能紊乱和精神状态恶化外，其他不良反应均消失。PHT组不良反应发生率上级。由Elsevier Ltd代表英国癫痫协会出版。
Purpose: To determine the utility and tolerability of levetiracetam (LEV) compared to phenytoin (PHT) in preventing clinical seizures in patients with subarachnoid hemorrhage (SAH).Methods: Utility and tolerability of PHT and LEV in patients with SAH were determined by the occurrence of breakthrough clinical seizures or adverse events necessitating a change of medication. Comparisons were performed with Chi-square tests.Results: All 176 patients were initially treated with PHT. No breakthrough clinical seizures occurred. In 70 (39.8%) patients, PHT was replaced with LEV due to adverse events including elevation of transaminases, thrombocytopenia, unexplained fever, rash, gastrointestinal disturbance, and worsening mental status. After switching to LEV, all adverse effects resolved except gastrointestinal disturbance and worsening mental Status in 4 patients, Adverse events Occurred more often in patients taking PHT.Conclusions: In patients with SAH, LEV appears to have superior tolerability compared to PHT. Published by Elsevier Ltd on behalf of British Epilepsy Association.